Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery

Chang Gon Kim, Joong Bae Ahn, Sang Joon Shin, Seung Hoon Beom, Su Jin Heo, Hyung Soon Park, Jee Hung Kim, Eun Ah Choe, Woong Sub Koom, Hyuk Hur, Byung Soh Min, Nam Kyu Kim, Hoguen Kim, Chan Kim, Inkyung Jung, Minkyu Jung

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: We aimed to explore the clinical benefit of adjuvant chemotherapy (AC) with fluoropyrimidine in patients with ypT0-3N0 rectal cancer after preoperative chemoradiation therapy (CRT) followed by total mesorectal excision (TME). Methods: Patients with ypT0-3N0 rectal cancer after preoperative CRT and TME were included using prospectively collected tumor registry cohort between January 2001 and December 2013. Patients were categorized into two groups according to the receipt of AC. Disease-free survival (DFS) and overall survival (OS) were compared between the adjuvant and observation groups. To control for potential confounding factors, we also calculated propensity scores and performed propensity score-matched analysis for DFS and OS. Results: Of the 339 evaluated patients, 87 patients (25.7%) did not receive AC. There were no differences in DFS (hazard ratio [HR], 0.921; 95% confidence interval [CI], 0.562-1.507; P = 0.742) and OS (HR, 0.835; 95% CI, 0.423-1.648; P = 0.603) between the adjuvant and observation groups. After propensity score matching, DFS (HR, 1.129; 95% CI, 0.626-2.035; P = 0.688) and OS (HR, 1.200; 95% CI, 0.539-2.669; P = 0.655) did not differ between the adjuvant and observation groups. Advanced T stage and positive resection margin were independently associated with inferior DFS and OS on multivariate analysis. Conclusions: AC did not improve DFS and OS for patients with ypT0-3N0 rectal cancer after preoperative CRT followed by TME in this cohort study. The confirmative role of AC in locally advanced rectal cancer should be evaluated in prospective randomized trials with a larger sample size.

Original languageEnglish
Article number615
JournalBMC cancer
Volume17
Issue number1
DOIs
Publication statusPublished - 2017 Sep 2

Fingerprint

Adjuvant Chemotherapy
Rectal Neoplasms
Disease-Free Survival
Propensity Score
Survival
Confidence Intervals
Observation
Therapeutics
Sample Size
Registries
Cohort Studies
Multivariate Analysis
Neoplasms

All Science Journal Classification (ASJC) codes

  • Genetics
  • Oncology
  • Cancer Research

Cite this

Kim, Chang Gon ; Ahn, Joong Bae ; Shin, Sang Joon ; Beom, Seung Hoon ; Heo, Su Jin ; Park, Hyung Soon ; Kim, Jee Hung ; Choe, Eun Ah ; Koom, Woong Sub ; Hur, Hyuk ; Min, Byung Soh ; Kim, Nam Kyu ; Kim, Hoguen ; Kim, Chan ; Jung, Inkyung ; Jung, Minkyu. / Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery. In: BMC cancer. 2017 ; Vol. 17, No. 1.
@article{2ade285062524282914d6a7567d11be9,
title = "Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery",
abstract = "Background: We aimed to explore the clinical benefit of adjuvant chemotherapy (AC) with fluoropyrimidine in patients with ypT0-3N0 rectal cancer after preoperative chemoradiation therapy (CRT) followed by total mesorectal excision (TME). Methods: Patients with ypT0-3N0 rectal cancer after preoperative CRT and TME were included using prospectively collected tumor registry cohort between January 2001 and December 2013. Patients were categorized into two groups according to the receipt of AC. Disease-free survival (DFS) and overall survival (OS) were compared between the adjuvant and observation groups. To control for potential confounding factors, we also calculated propensity scores and performed propensity score-matched analysis for DFS and OS. Results: Of the 339 evaluated patients, 87 patients (25.7{\%}) did not receive AC. There were no differences in DFS (hazard ratio [HR], 0.921; 95{\%} confidence interval [CI], 0.562-1.507; P = 0.742) and OS (HR, 0.835; 95{\%} CI, 0.423-1.648; P = 0.603) between the adjuvant and observation groups. After propensity score matching, DFS (HR, 1.129; 95{\%} CI, 0.626-2.035; P = 0.688) and OS (HR, 1.200; 95{\%} CI, 0.539-2.669; P = 0.655) did not differ between the adjuvant and observation groups. Advanced T stage and positive resection margin were independently associated with inferior DFS and OS on multivariate analysis. Conclusions: AC did not improve DFS and OS for patients with ypT0-3N0 rectal cancer after preoperative CRT followed by TME in this cohort study. The confirmative role of AC in locally advanced rectal cancer should be evaluated in prospective randomized trials with a larger sample size.",
author = "Kim, {Chang Gon} and Ahn, {Joong Bae} and Shin, {Sang Joon} and Beom, {Seung Hoon} and Heo, {Su Jin} and Park, {Hyung Soon} and Kim, {Jee Hung} and Choe, {Eun Ah} and Koom, {Woong Sub} and Hyuk Hur and Min, {Byung Soh} and Kim, {Nam Kyu} and Hoguen Kim and Chan Kim and Inkyung Jung and Minkyu Jung",
year = "2017",
month = "9",
day = "2",
doi = "10.1186/s12885-017-3624-7",
language = "English",
volume = "17",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

Kim, CG, Ahn, JB, Shin, SJ, Beom, SH, Heo, SJ, Park, HS, Kim, JH, Choe, EA, Koom, WS, Hur, H, Min, BS, Kim, NK, Kim, H, Kim, C, Jung, I & Jung, M 2017, 'Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery', BMC cancer, vol. 17, no. 1, 615. https://doi.org/10.1186/s12885-017-3624-7

Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery. / Kim, Chang Gon; Ahn, Joong Bae; Shin, Sang Joon; Beom, Seung Hoon; Heo, Su Jin; Park, Hyung Soon; Kim, Jee Hung; Choe, Eun Ah; Koom, Woong Sub; Hur, Hyuk; Min, Byung Soh; Kim, Nam Kyu; Kim, Hoguen; Kim, Chan; Jung, Inkyung; Jung, Minkyu.

In: BMC cancer, Vol. 17, No. 1, 615, 02.09.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery

AU - Kim, Chang Gon

AU - Ahn, Joong Bae

AU - Shin, Sang Joon

AU - Beom, Seung Hoon

AU - Heo, Su Jin

AU - Park, Hyung Soon

AU - Kim, Jee Hung

AU - Choe, Eun Ah

AU - Koom, Woong Sub

AU - Hur, Hyuk

AU - Min, Byung Soh

AU - Kim, Nam Kyu

AU - Kim, Hoguen

AU - Kim, Chan

AU - Jung, Inkyung

AU - Jung, Minkyu

PY - 2017/9/2

Y1 - 2017/9/2

N2 - Background: We aimed to explore the clinical benefit of adjuvant chemotherapy (AC) with fluoropyrimidine in patients with ypT0-3N0 rectal cancer after preoperative chemoradiation therapy (CRT) followed by total mesorectal excision (TME). Methods: Patients with ypT0-3N0 rectal cancer after preoperative CRT and TME were included using prospectively collected tumor registry cohort between January 2001 and December 2013. Patients were categorized into two groups according to the receipt of AC. Disease-free survival (DFS) and overall survival (OS) were compared between the adjuvant and observation groups. To control for potential confounding factors, we also calculated propensity scores and performed propensity score-matched analysis for DFS and OS. Results: Of the 339 evaluated patients, 87 patients (25.7%) did not receive AC. There were no differences in DFS (hazard ratio [HR], 0.921; 95% confidence interval [CI], 0.562-1.507; P = 0.742) and OS (HR, 0.835; 95% CI, 0.423-1.648; P = 0.603) between the adjuvant and observation groups. After propensity score matching, DFS (HR, 1.129; 95% CI, 0.626-2.035; P = 0.688) and OS (HR, 1.200; 95% CI, 0.539-2.669; P = 0.655) did not differ between the adjuvant and observation groups. Advanced T stage and positive resection margin were independently associated with inferior DFS and OS on multivariate analysis. Conclusions: AC did not improve DFS and OS for patients with ypT0-3N0 rectal cancer after preoperative CRT followed by TME in this cohort study. The confirmative role of AC in locally advanced rectal cancer should be evaluated in prospective randomized trials with a larger sample size.

AB - Background: We aimed to explore the clinical benefit of adjuvant chemotherapy (AC) with fluoropyrimidine in patients with ypT0-3N0 rectal cancer after preoperative chemoradiation therapy (CRT) followed by total mesorectal excision (TME). Methods: Patients with ypT0-3N0 rectal cancer after preoperative CRT and TME were included using prospectively collected tumor registry cohort between January 2001 and December 2013. Patients were categorized into two groups according to the receipt of AC. Disease-free survival (DFS) and overall survival (OS) were compared between the adjuvant and observation groups. To control for potential confounding factors, we also calculated propensity scores and performed propensity score-matched analysis for DFS and OS. Results: Of the 339 evaluated patients, 87 patients (25.7%) did not receive AC. There were no differences in DFS (hazard ratio [HR], 0.921; 95% confidence interval [CI], 0.562-1.507; P = 0.742) and OS (HR, 0.835; 95% CI, 0.423-1.648; P = 0.603) between the adjuvant and observation groups. After propensity score matching, DFS (HR, 1.129; 95% CI, 0.626-2.035; P = 0.688) and OS (HR, 1.200; 95% CI, 0.539-2.669; P = 0.655) did not differ between the adjuvant and observation groups. Advanced T stage and positive resection margin were independently associated with inferior DFS and OS on multivariate analysis. Conclusions: AC did not improve DFS and OS for patients with ypT0-3N0 rectal cancer after preoperative CRT followed by TME in this cohort study. The confirmative role of AC in locally advanced rectal cancer should be evaluated in prospective randomized trials with a larger sample size.

UR - http://www.scopus.com/inward/record.url?scp=85028661476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028661476&partnerID=8YFLogxK

U2 - 10.1186/s12885-017-3624-7

DO - 10.1186/s12885-017-3624-7

M3 - Article

C2 - 28865435

AN - SCOPUS:85028661476

VL - 17

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 615

ER -